Amyloidosis trials in Martinique

1 trial · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  Where

  Fort-de-France

  Age

  18 years to 75 years

  People

  587 worldwide

  Run by

  Eidos Therapeutics, a BridgeBio company

  See details and how to joinNCT06563895 · EU 2024-513547-82-00